Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Faces Price Pressures In US On Generic Gleevec

Executive Summary

India’s biggest drug-maker, Sun Pharmaceutical Industries Ltd., has reported a more than tripling of its quarterly profit thanks to US sales of a generic version of Novartis AG’s leukemia blockbuster Gleevec. But now its 180-day sales exclusivity window has closed and generic rivals are launching in the US market, pushing prices down.

You may also be interested in...



Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure

Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.

Sun Chief Sees ‘New Normal’ For First-To-File ANDAs Amid US Price Pressure

Sun Pharmaceutical Industries reported weak fourth quarter earnings amid US pricing pressure and the management has signaled a challenging FY2018 in store.

Manufacturing Woes Continue To Plague Dr Reddy’s; Are Generic Gleevec Launch Plans Under Threat?

Dr Reddy’s Laboratories was battered on Indian bourses on March 9 after one of the firm’s formulation sites failed to get a clean chit from the FDA, piling up pressure on important US generic launch timelines.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC097139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel